2017
Company founded
2018
Tens of millions USD of A round raised Preliminary R&D pipeline established
Jan，2019
Opening of InxMed Shanghai & Beijing offices
Sep, 2019
Ifebemtinib Received US FDA IND Approval
Oct, 2019
Achieved clinical collaboration with Roche for Ifebemtinib co-development
Dec, 2019
Ifebemtinib Phase I Clinical Trial in China approved
Jan，2020
Achieved clinical collaboration with Merck for Ifebemtinib co-development
Mar，2020
First patient enrolled in the US
Apr，2020
Investigational New Drug (IND) application approved for Ifebemtinib combined with chemotherapy for the treatment of high-grade serous ovarian cancer
Jul，2020
First patient enrolled in China
Sep，2020
Closed 130 million RMB of A+ round
Feb，2021
Opening of InxMed R&D and Translational Research Center
Aug，2021
Ifebemtinib Received US FDA Fast Track Designation
Sep，2021
Published the result of Ifebemtinib synergized with KRAS G12C Inhibitors to improve treatment outcomes for KRAS G12C mutant cancers
Mar, 2022
Closed US $50M Series B Financing
Apr, 2022
Ifebemtinib Received NMPA Breakthrough Designation
May, 2022
Closed US $15M Series B+ Financing
Jun，2022
Announced that result of an open-label phase Ib trial of Ifebemtinib in PROC in ASCO 2022
Sep，2022
Announced first patient dosed in pivotal phase 2 study of Ifebemtinib in PROC
Oct，2022
Released data demonstrating Ifebemtinib therapeutic potential in metastatic melanoma at SMR 2022
Aug，2023
Received approval to initiate phase I clinical trial in China for OMTX705
Oct，2023
Released data at 14th Annual World ADC highlighting synergy of Ifebemtinib with ADCs and novel stroma targeting pipeline
Oct，2023
Released data demonstrating Ifebemtinib trending toward survival benefit for PROC and TNBC at ESMO 2023
Dec，2023
Entered license agreement with Escugen to develop next-generation ADCs
Jun，2024
Released Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in 1L NSCLC with KRAS G12C Mutation
Oct，2024
Released data Ifebemtinib improving therapeutic window of ADC at 15th Annual World ADC
Nov，2024
Received Breakthrough Therapy Designation by China NMPA for 1L NSCLC with KRAS G12C Mutation
Apr，2025
Opening of InxMed Shenzhen office
Aug，2025
Closed US $33.72M Series C Financing
Aug，2025
Received the third Breakthrough Therapy Designation by China NMPA for 2L+ CRC with KRAS G12C Mutation
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE